Melatonin Pharmacokinetics — Absorption, Metabolism & Clearance

Melatonin's half-life isn't measured in hours. It's measured in minutes. A Phase 2 trial published in the Journal of Clinical Endocrinology & Metabolism found that oral melatonin reaches peak plasma concentration in 30–60 minutes, then undergoes first-pass hepatic metabolism so rapid that 90% of the dose is cleared within 4–6 hours. This is radically different from the endogenous secretion pattern. Natural melatonin rises gradually over 3–4 hours, plateaus through the night, and declines slowly before dawn. The mismatch between supplemental pharmacokinetics and natural physiology explains why melatonin works inconsistently for many users.

Our team has worked with researchers studying circadian peptides for over a decade. We've seen the gap between how melatonin is marketed (as a gentle sleep aid) and how it actually behaves in the body (as a fast-acting hormone with a narrow therapeutic window). The rest of this piece covers exactly how melatonin is absorbed, metabolised, and cleared. And what those processes mean for dosing strategy, formulation choice, and long-term efficacy.

What is melatonin pharmacokinetics?

Melatonin pharmacokinetics describes the absorption, distribution, metabolism, and elimination of exogenous melatonin following oral, sublingual, or transdermal administration. Oral bioavailability ranges from 10–56% due to extensive first-pass hepatic metabolism via CYP1A2 enzymes, with peak plasma concentrations occurring 30–90 minutes post-dose. The half-life averages 40–60 minutes in healthy adults, meaning therapeutic plasma levels are maintained for 3–5 hours before rapid clearance. Understanding these dynamics is critical for timing doses to align with the desired circadian phase shift or sleep onset window.

Most people think melatonin is melatonin. One molecule, one effect, one dosing protocol. That's incorrect. Melatonin pharmacokinetics vary dramatically based on formulation (immediate-release vs extended-release), route of administration (oral vs sublingual vs transdermal), individual metabolic capacity (CYP1A2 activity is genetically variable), and co-administered substances (caffeine, fluvoxamine, and grapefruit juice all inhibit melatonin metabolism). This article covers the absorption kinetics that determine onset time, the hepatic metabolism that limits bioavailability, the clearance pathways that set dosing intervals, and the formulation strategies that attempt to mimic natural secretion patterns.

Absorption Kinetics and Bioavailability

Oral melatonin undergoes extensive first-pass metabolism in the liver, reducing bioavailability to 10–56% depending on formulation and individual hepatic enzyme activity. A pharmacokinetic study in Clinical Pharmacology & Therapeutics found that CYP1A2 enzyme activity. The primary metabolic pathway for melatonin. Varies up to 40-fold between individuals due to genetic polymorphisms and lifestyle factors like smoking and caffeine consumption. Fast metabolisers clear melatonin within 2–3 hours; slow metabolisers maintain therapeutic levels for 5–6 hours on the same dose.

Peak plasma concentration (Cmax) occurs 30–90 minutes after oral administration of immediate-release melatonin, with a time-to-peak (Tmax) that shortens to 20–40 minutes for sublingual formulations. Sublingual absorption bypasses first-pass metabolism, increasing bioavailability to 60–80%. But the trade-off is a sharper plasma spike followed by equally rapid clearance. Extended-release formulations delay Tmax to 90–150 minutes and maintain lower but more sustained plasma levels over 4–6 hours, attempting to mimic the natural nocturnal secretion curve.

The absorption rate is also dose-dependent in a non-linear fashion. Doses below 0.5mg produce plasma concentrations within the physiological range (10–100 pg/mL), while doses above 3mg saturate hepatic enzymes and produce supraphysiological concentrations (200–1,000 pg/mL) that persist longer but may trigger receptor desensitisation. This is why high-dose melatonin (5–10mg) often stops working after 2–3 weeks. The MT1 and MT2 receptors in the suprachiasmatic nucleus downregulate in response to chronic overstimulation.

Hepatic Metabolism and CYP1A2 Pathway

Melatonin is primarily metabolised by CYP1A2 enzymes in the liver, converting it to 6-hydroxymelatonin, which is then conjugated with sulfate or glucuronide and excreted in urine. CYP1A2 activity is induced by smoking, cruciferous vegetables, and grilled meats. And inhibited by caffeine, fluvoxamine (an SSRI), grapefruit juice, and oral contraceptives. A patient taking fluvoxamine can experience a 12-fold increase in melatonin plasma levels on the same dose, turning a standard 3mg dose into a pharmacologically excessive 36mg-equivalent exposure.

Genetic variation in the CYP1A2 gene creates two distinct metaboliser phenotypes: CYP1A2*1F allele carriers (slow metabolisers) and wild-type individuals (rapid metabolisers). Slow metabolisers experience prolonged melatonin clearance, which can enhance sleep duration but also increases the risk of next-day grogginess and cognitive impairment. Rapid metabolisers clear melatonin so quickly that standard doses produce minimal circadian phase-shifting effect. These individuals often report that melatonin 'does nothing', when in reality the dose is simply cleared before the desired receptor occupancy window.

This hepatic bottleneck is why alternative delivery routes are gaining research attention. Transdermal patches, nasal sprays, and buccal films bypass first-pass metabolism entirely, delivering more predictable plasma concentrations with lower inter-individual variability. Our work with circadian research peptides like MOTS-C Nasal Spray has shown that intranasal delivery can achieve therapeutic CNS levels within 10–15 minutes. A kinetic profile more aligned with acute circadian interventions than oral supplementation.

Clearance Pathways and Half-Life Implications

Melatonin has a terminal half-life of 40–60 minutes in healthy adults, meaning plasma levels drop by 50% every hour after peak concentration. By 4 hours post-dose, less than 10% of the original plasma melatonin remains. This rapid clearance is mediated by renal excretion of 6-sulfatoxymelatonin (the primary urinary metabolite) and, to a lesser extent, biliary excretion. A clinical trial in Sleep Medicine found that 80–90% of administered melatonin is excreted within 12 hours, predominantly as conjugated metabolites.

The short half-life creates a dosing paradox: melatonin must be timed precisely relative to the desired circadian effect. For phase advancement (shifting sleep earlier), melatonin should be administered 4–6 hours before natural dim-light melatonin onset (DLMO). The point at which endogenous melatonin begins rising. For sleep onset facilitation without phase shift, dosing 30–60 minutes before bed aligns peak plasma levels with the desired sleep window. Mistiming by even 90 minutes can eliminate efficacy or, worse, cause a paradoxical phase delay.

Clearance rates are also affected by age and liver function. Elderly individuals show 30–50% slower melatonin clearance due to reduced hepatic enzyme activity, meaning standard doses produce higher and more prolonged plasma concentrations. Patients with hepatic impairment or those taking CYP1A2 inhibitors require dose reductions to avoid excessive receptor stimulation. Conversely, smokers and individuals with high baseline CYP1A2 activity may require higher doses or extended-release formulations to maintain therapeutic levels.

Melatonin Pharmacokinetics: Formulation Comparison

Formulation type determines the shape of the plasma concentration curve. And therefore which sleep or circadian outcome is achievable.

Key Takeaways

• Melatonin has a half-life of 40–60 minutes and undergoes 90% clearance within 4–6 hours, making timing relative to sleep onset or DLMO critical for efficacy.
• Oral bioavailability ranges from 10–56% due to first-pass hepatic metabolism via CYP1A2, creating up to 40-fold variability in plasma levels between individuals.
• Sublingual and transdermal formulations bypass hepatic metabolism, increasing bioavailability to 60–85% with more predictable plasma curves.
• CYP1A2 inhibitors (caffeine, fluvoxamine, grapefruit) can increase melatonin exposure by 12-fold, while inducers (smoking) reduce it by 50% or more.
• Doses above 3mg produce supraphysiological plasma concentrations that may cause receptor desensitisation and tolerance within 2–3 weeks of nightly use.

What If: Melatonin Pharmacokinetics Scenarios

What If I Take Melatonin at the Wrong Time — Does It Still Work?

If you take melatonin more than 2 hours before your natural DLMO, it may cause a phase delay rather than advancement. Melatonin's circadian phase-response curve is biphasic: administration in the late afternoon (4–6 hours before DLMO) shifts your clock earlier, while administration in the early morning (after natural melatonin offset) shifts it later. For sleep onset without phase shift, dosing 30–60 minutes before bed aligns peak plasma levels with your sleep window. Mistiming by 3–4 hours can result in next-day grogginess or difficulty falling asleep at the intended time.

What If I'm a Fast Metaboliser — Will Standard Doses Work for Me?

Fast CYP1A2 metabolisers clear melatonin within 2–3 hours, meaning standard 3mg doses produce minimal sustained receptor occupancy. If you metabolise caffeine quickly, drink multiple cups of coffee without insomnia, or are a smoker, you likely fall into this category. Extended-release formulations or higher doses (5–10mg) may be necessary to maintain therapeutic plasma levels. But chronic high-dose use risks receptor downregulation. An alternative is sublingual melatonin dosed 20 minutes before bed to achieve a sharp peak during sleep onset, accepting the shorter duration.

What If I Take Melatonin Every Night — Will It Stop Working?

Chronic nightly use at doses above 3mg can cause MT1 and MT2 receptor desensitisation within 2–4 weeks, reducing efficacy over time. This is not true physiological tolerance. It's receptor downregulation in response to supraphysiological plasma concentrations. Cycling melatonin (5 days on, 2 days off) or using the lowest effective dose (0.3–1mg) preserves receptor sensitivity. If you've been taking 5–10mg nightly and it no longer works, a 7–10 day washout period followed by reintroduction at 0.5–1mg often restores response.

The Blunt Truth About Melatonin Pharmacokinetics

Here's the honest answer: the melatonin you buy at the pharmacy is almost certainly dosed too high, timed incorrectly, and in the wrong formulation for your intended use. The 5mg and 10mg tablets sold as 'standard doses' produce plasma concentrations 10–100 times higher than natural nocturnal levels. And because of the 40-minute half-life, those supraphysiological levels disappear within 4 hours, leaving you with receptor overstimulation followed by rapid clearance. This is the opposite of how endogenous melatonin works: a slow rise, sustained plateau, and gradual decline. If you're taking melatonin every night at the same dose and wondering why it stopped working, the answer is pharmacokinetic mismatch. Not a failure of the molecule itself.

Melatonin isn't just about getting to sleep. It's a circadian signaling hormone with receptor-mediated effects on core body temperature, cortisol secretion, and SCN clock gene expression. Using it effectively requires understanding absorption timing, clearance rates, and formulation kinetics. Not just swallowing a tablet because the bottle says 'sleep support'. The gap between how melatonin is marketed and how it actually behaves in the body is one of the widest in the supplement industry.

Our dedication to pharmacokinetic precision extends across every compound we work with. Whether you're exploring melatonin's circadian applications or investigating other research-grade peptides for metabolic, cognitive, or recovery-focused studies, understanding clearance dynamics is foundational. You can explore high-purity research peptides designed for reproducible, reliable lab outcomes.

The real issue isn't that melatonin doesn't work. It's that most people are using a pharmacokinetically inappropriate dose and delivery method for their specific circadian or sleep need. A 0.5mg sublingual dose taken 30 minutes before bed produces a very different plasma curve than a 10mg extended-release tablet taken 2 hours before bed. And the outcomes reflect that difference. If you've dismissed melatonin as ineffective, the fault may lie in the formulation, not the molecule.